"CatSci's purpose is to get new medicines into the hands of patients in need and partnering the game changing siRNA drug development potential at Argonaute is a collaboration we are very excited about. Together we are exploring solutions for the manufacture of high-quality siRNA drug substance to enable robust preclinical studies and at scale for clinical trials."
- Dr Ross Burn (CEO, CatSci)
“Our businesses interact seamlessly to ensure IP generation and business objectives are robust, enforceable and value generating.”
- Rob Docherty PhD EPA MBA (Director, Symbiosis IP)
“At Carbometrics we specialise in the synthesis and bioconjugation of synthetic molecular recognition agents. Our collaboration with Argonaute is an excellent fusion of competencies and an exciting opportunity for us to use our chemistry expertise to augment what is already a paradigm shifting siRNA platform to create revolutionary therapeutics”
- Andy Chapman (CEO and Co-founder, Carbometrics)
Neurofibromatosis (NF) is a condition that causes tumors to develop along the brainstem and spinal cord. The Peripheral Nerve Sheath tumors developed in NF patients are susceptible to metastasis and forming cancer. NF patients also may experience vision loss due to tumor growth along the optic, skin abnormalities such as skin freckling and cafe au lait spots, developmental delays, and bone deformities.
While it is a genetic condition, half of NF cases are caused by a spontaneous mutations, and not inherited from family. There are two types of NF known as neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2). Additionally, a third condition sharing many symptoms of NF has been recognized and is known as schwannomatosis.
NF1 is cause by a mutation in one copy of the tumor suppressor gene known as the NF1 gene. This gene controls the production of a protein known as neurofibromin, and when lost, the cell is unable to regulate cell growth.
Meet the team ↗